Serum proteomic patterns for detection of prostate cancer.
Pathologic states within the prostate may be reflected by changes in serum proteomic patterns. To test this hypothesis, we analyzed serum proteomic mass spectra with a bioinformatics tool to reveal the most fit pattern that discriminated the training set of sera of men with a histopathologic diagnosis of prostate cancer (serum prostate-specific antigen [PSA] > or =4 ng/mL) from those men without prostate cancer (serum PSA level <1 ng/mL). Mass spectra of blinded sera (N = 266) from a test set derived from men with prostate cancer or men without prostate cancer were matched against the discriminating pattern revealed by the training set. A predicted diagnosis of benign disease or cancer was rendered based on similarity to the discriminating pattern discovered from the training set. The proteomic pattern correctly predicted 36 (95%, 95% confidence interval [CI] = 82% to 99%) of 38 patients with prostate cancer, while 177 (78%, 95% CI = 72% to 83%) of 228 patients were correctly classified as having benign conditions. For men with marginally elevated PSA levels (4-10 ng/mL; n = 137), the specificity was 71%. If validated in future series, serum proteomic pattern diagnostics may be of value in deciding whether to perform a biopsy on a man with an elevated PSA level.
Petricoin
Emanuel F
EF
Food and Drug Administration (FDA)-National Cancer Institute (NCI) Clinical Proteomics Program, Department of Therapeutic Proteins/Center for Biologics Evaluation and Research (CBER), Bethesda, MD, USA. petricoin@cber.fda.gov
Ornstein
David K
DK
Paweletz
Cloud P
CP
Ardekani
Ali
A
Hackett
Paul S
PS
Hitt
Ben A
BA
Velassco
Alfredo
A
Trucco
Christian
C
Wiegand
Laura
L
Wood
Kamillah
K
Simone
Charles B
CB
Levine
Peter J
PJ
Linehan
W Marston
WM
Emmert-Buck
Michael R
MR
Steinberg
Seth M
SM
Kohn
Elise C
EC
Liotta
Lance A
LA
D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011469:Prostatic Diseases / Q000097:blood / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000276:immunology; D020543:Proteome / Q000032:analysis*
D014408:Biomarkers, Tumor; D020543:Proteome; D017430:Prostate-Specific Antigen